Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from DXCM

What to Expect From DexCom's Q4 2024 Earnings Report

DexCom is gearing up to release its fourth-quarter earnings next month, and analysts forecast single-digit profit growth.

Barchart

Is DexCom Stock Underperforming the Nasdaq?

Despite DexCom's lagging performance relative to the Nasdaq Composite over the past year, Wall Street analysts maintain a strong bullish outlook on the stock's prospects.

Barchart

Are Wall Street Analysts Predicting DexCom Stock Will Climb or Sink?

Despite DexCom’s underperformance relative to the broader market over the past year, Wall Street analysts remain bullish about the stock’s prospects.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Here's What to Expect From DexCom's Next Earnings Report

DexCom is poised to announce its third-quarter results later this month, with analysts predicting a double-digit decline in the company's earnings.

Barchart

Is DexCom Stock Underperforming the S&P 500?

Despite DexCom’s underperformance compared to the S&P 500 Index over the past year, Wall Street analysts are highly bullish about the stock’s prospects.

Barchart

Is Wall Street Bullish or Bearish on DexCom Stock?

Despite DexCom lagging behind the broader market over the past year, Wall Street analysts remain bullish on the stock’s prospects.

Barchart

Dexcom Stock Sinks on Sales Miss, Guidance Cut: What to Know

Dexcom stock is crashing Friday after the glucose monitoring company reported dismal Q2 revenue and slashed its full-year sales guidance. Here's what you need to know.

Kiplinger

Read news from The Economist, FT, and more,
with one subscription

3 Top-Rated Healthcare Stocks With 20% to 35% Upside Potential

Amid a broader market rotation out of Big Tech stocks, investors can consider these three top-rated healthcare stocks with double-digit upside potential.

Barchart

Earnings Preview: What to Expect From DexCom's Report

DexCom is gearing up to announce its second-quarter results this month, and analysts are anticipating a double-digit increase in the company’s bottom-line figure.

Barchart

How Is DexCom's Stock Performance Compared to Other Medical Devices Stocks?

Despite DexCom’s underperformance compared to its industry, Wall Street analysts remain optimistic about the stock’s prospects.

Barchart

3 Healthcare Stocks Benefiting From an Aging Population

The healthcare industry is poised for tremendous growth driven by the aging population and rising incidence of chronic diseases. Hence, quality healthcare stocks, Danaher (DHR), Amgen (AMGN), and DexCom (DXCM), benefiting from an aging population, might be worth looking into. Read more….

StockNews.com

This Is What Whales Are Betting On DexCom

Someone with a lot of money to spend has taken a bullish stance on DexCom (NASDAQ:DXCM). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Here's How Much You Would Have Made Owning DexCom Stock In The Last 15 Years

DexCom (NASDAQ:DXCM) has outperformed the market over the past 15 years by 20.9% on an annualized basis producing an average annual return of 27.35%. Currently, DexCom has a market capitalization of $30.77 billion.

Benzinga

If You Invested $1000 In This Stock 5 Years Ago, You Would Have $16,000 Today

DexCom (NASDAQ:DXCM) has outperformed the market over the past 5 years by 64.52% on an annualized basis producing an average annual return of 74.42%. Currently, DexCom has a market capitalization of $115.32 billion.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Here's How Much You Would Have Made Owning DexCom Stock In The Last 15 Years

DexCom (NASDAQ:DXCM) has outperformed the market over the past 15 years by 22.06% on an annualized basis producing an average annual return of 28.95%. Currently, DexCom has a market capitalization of $29.24 billion.

Benzinga

What Are Whales Doing With DexCom

A whale with a lot of money to spend has taken a noticeably bearish stance on DexCom. Looking at options history for DexCom (NASDAQ:DXCM) we detected 25 strange trades.

Benzinga

Dexcom In Talks To Acquire Insulet, Create a Giant In Diabetes Devices: Bloomberg

Dexcom Inc (NYSE:DXCM) is reportedly in talks to acquire medical-device company Insulet Corporation (NASDAQ: PODD) to create a giant in diabetes devices, according to people with knowledge of the matter. According to Bloomberg, talks between the companies are ongoing, and an agreement could be reached in the coming weeks. Discussions could still be delayed or fall…

Benzinga

DexCom Earnings Perspective: Return On Invested Capital

Pulled from Benzinga Pro data, DexCom (NASDAQ:DXCM) posted Q1 earnings of $97.30 million, an increase from Q4 of 601.55%. Sales dropped to $628.80 million, a 9.94% decrease between quarters.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

If You Invested $1000 In DexCom 10 Years Ago, Here's How Much You Would Have Today

DexCom (NASDAQ:DXCM) has outperformed the market over the past 10 years by 32.66% on an annualized basis producing an average annual return of 44.4%. Currently, DexCom has a market capitalization of $39.95 billion.

Benzinga

Read Here Why Did This Analyst Cut DexCom's Price Target

Benzinga

Here's How Much $100 Invested In DexCom 5 Years Ago Would Be Worth Today

DexCom (NASDAQ:DXCM) has outperformed the market over the past 5 years by 32.15% on an annualized basis producing an average annual return of 45.92%. Currently, DexCom has a market capitalization of $49.71 billion.

Benzinga

Dexcom G7 Continuous Glucose Monitoring System Receives European CE Mark

DexCom Inc's (NASDAQ: DXCM) Dexcom G7 Continuous Glucose Monitoring (CGM) System has

Benzinga

DexCom Stock Falls As Q4 Profit, FY22 Sales Outlook Trail Wall Street Estimates

DexCom Inc's (NASDAQ: DXCM)

StockNews.com

2 Upgraded Diabetes Stocks to Add to Your Watchlist

Diabetes has become one of the leading causes of death for Americans, claiming more than 100,000 lives in 2021. But the disease’s prevalence represents promising prospects for the diabetes care devices market. Given this backdrop, analysts have recently upgraded diabetes stocks DexCom (DXCM) and Insulet (PODD). Thus, these stocks could…

Benzinga

Will Chart Analysts Notice Bad Omen on DexCom's Chart

If history is any guide, there may be trouble ahead for shares of DexCom (NASDAQ:DXCM). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.

1 2 3

Organisations

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.